472 related articles for article (PubMed ID: 28683707)
1. Docetaxel in hormone-sensitive advanced prostate cancer; GENESIS-SEFH evaluation reporta.
García de Paredes Esteban JC; Alegre Del Rey EJ; Asensi Díez R
Farm Hosp; 2017 Jul; 41(4):550-558. PubMed ID: 28683707
[TBL] [Abstract][Full Text] [Related]
2. Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials.
van Soest RJ; de Wit R
BMC Med; 2015 Dec; 13():304. PubMed ID: 26695172
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective.
Zheng HR; Wen F; Wu YF; Wheeler JRC; Li Q
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27145493
[TBL] [Abstract][Full Text] [Related]
4. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Gravis G; Fizazi K; Joly F; Oudard S; Priou F; Esterni B; Latorzeff I; Delva R; Krakowski I; Laguerre B; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M
Lancet Oncol; 2013 Feb; 14(2):149-58. PubMed ID: 23306100
[TBL] [Abstract][Full Text] [Related]
5. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
Damodaran S; Lang JM; Jarrard DF
J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
[TBL] [Abstract][Full Text] [Related]
6. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
[TBL] [Abstract][Full Text] [Related]
7. Commentary on "Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial." Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M, Medical Oncology and Biostatistics, Institut Paoli-Calmettes, Marseille, France. Lancet Oncol 2013;14(2):149-58 [Epub 2013 Jan 8].
Trump DL
Urol Oncol; 2013 Nov; 31(8):1845. PubMed ID: 24210084
[TBL] [Abstract][Full Text] [Related]
8. Contemporary Management of the Newly Diagnosed Prostate Cancer Patient with Metastatic Disease at Presentation.
Xu L; Pachynski RK
Curr Urol Rep; 2018 Aug; 19(10):79. PubMed ID: 30105573
[TBL] [Abstract][Full Text] [Related]
9. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.
Gravis G; Boher JM; Chen YH; Liu G; Fizazi K; Carducci MA; Oudard S; Joly F; Jarrard DM; Soulie M; Eisenberger MJ; Habibian M; Dreicer R; Garcia JA; Hussain MHM; Kohli M; Vogelzang NJ; Picus J; DiPaola R; Sweeney C
Eur Urol; 2018 Jun; 73(6):847-855. PubMed ID: 29475737
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
Botrel TE; Clark O; Lima Pompeo AC; Horta Bretas FF; Sadi MV; Ferreira U; Borges Dos Reis R
PLoS One; 2016; 11(6):e0157660. PubMed ID: 27308831
[TBL] [Abstract][Full Text] [Related]
11. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Tucci M; Bertaglia V; Vignani F; Buttigliero C; Fiori C; Porpiglia F; Scagliotti GV; Di Maio M
Eur Urol; 2016 Apr; 69(4):563-573. PubMed ID: 26422676
[TBL] [Abstract][Full Text] [Related]
12. [Docetaxel for metastatic prostate cancer: early is better].
Gietema JA; Oosting SF
Ned Tijdschr Geneeskd; 2016; 160():D215. PubMed ID: 27405569
[TBL] [Abstract][Full Text] [Related]
13. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
McNamara M; Sweeney C; Antonarakis ES; Armstrong AJ
Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):306-318. PubMed ID: 29263421
[TBL] [Abstract][Full Text] [Related]
14. Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.
Hoyle AP; Ali A; James ND; Cook A; Parker CC; de Bono JS; Attard G; Chowdhury S; Cross WR; Dearnaley DP; Brawley CD; Gilson C; Ingleby F; Gillessen S; Aebersold DM; Jones RJ; Matheson D; Millman R; Mason MD; Ritchie AWS; Russell M; Douis H; Parmar MKB; Sydes MR; Clarke NW;
Eur Urol; 2019 Dec; 76(6):719-728. PubMed ID: 31447077
[TBL] [Abstract][Full Text] [Related]
15. Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
Fizazi K; Jenkins C; Tannock IF
Ann Oncol; 2015 Aug; 26(8):1660-7. PubMed ID: 26002607
[TBL] [Abstract][Full Text] [Related]
16. [Patients with metastatic prostate cancer : Recommendations for primary hormonal or chemohormonal therapy].
Ohlmann CH
Urologe A; 2017 Nov; 56(11):1424-1429. PubMed ID: 28983763
[TBL] [Abstract][Full Text] [Related]
17. Doxetaxel: new indication. Prostate cancer: a few more weeks.
Prescrire Int; 2006 Feb; 15(81):6-7. PubMed ID: 16548096
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy at First Diagnosis of Advanced Prostate Cancer - Revolution or Evolution? Findings from a British Uro-oncology Group UK Survey to Evaluate Oncologists' Views on First-line Docetaxel in Combination with Androgen Deprivation Therapy in Castrate-sensitive Metastatic and High-risk/Locally Advanced Prostate Cancer.
Davda R; Hughes S; Jones R; Crabb SJ; Troup J; Payne H
Clin Oncol (R Coll Radiol); 2016 Jun; 28(6):376-85. PubMed ID: 26874654
[TBL] [Abstract][Full Text] [Related]
19. Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Morris MJ; Rumble RB; Basch E; Hotte SJ; Loblaw A; Rathkopf D; Celano P; Bangs R; Milowsky MI
J Clin Oncol; 2018 May; 36(15):1521-1539. PubMed ID: 29608397
[TBL] [Abstract][Full Text] [Related]
20. Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.
Landre T; Guetz GD; Chouahnia K; Fossey-Diaz V; Taleb C; Culine S
Clin Genitourin Cancer; 2019 Aug; 17(4):e806-e813. PubMed ID: 31227430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
